Chlorotrianisene-d9

Chlorotrianisene-d9

• CAS Number: 1276197-26-2
• UNSPSC Description: Chlorotrianisene-d9 is the deuterium labeled Chlorotrianisene. Chlorotrianisene is a long-acting non-steroidal estrogen and an orally active estrogen receptor modulator. Chlorotrianisene exhibits antiestrogenic activity. Chlorotrianisene potently inhibits the enzyme COX-1 and inhibits platelet aggregation in whole blood[1][2][3].
• Target Antigen: COX; Estrogen Receptor/ERR; Isotope-Labeled Compounds
• Type: Isotope-Labeled Compounds
• Related Pathways: Immunology/Inflammation;Others;Vitamin D Related/Nuclear Receptor
• Field of Research: Endocrinology; Cardiovascular Disease
• Solubility: 10 mM in DMSO
• Smiles: Cl/C(C1=CC=C(C=C1)OC([2H])([2H])[2H])=C(C2=CC=C(C=C2)OC([2H])([2H])[2H])\C3=CC=C(C=C3)OC([2H])([2H])[2H]
• Molecular Weight: 389.92
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Ruenitz PC, et al. Estrogenic tamoxifen derivatives: categorization of intrinsic estrogenicity in MCF-7 cells. J Steroid Biochem Mol Biol. 1997 Nov-Dec;63(4-6):203-9.|[3]Lounkine E, et al. Large-scale prediction and testing of drug activity on side-effect targets. Nature. 2012 Jun 10;486(7403):361-7.|[4]Kupfer D, et al. Inactivation of the uterine estrogen receptor binding of estradiol during P-450 catalyzed metabolism of chlorotrianisene (TACE). Speculation that TACE antiestrogenic activity involves covalent binding to the estrogen receptor. FEBS Lett. 1990 Feb 12;261(1):59-62.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported